New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex
by an order of magnitude and delivers industry-leading speed and
throughput
PLEASANTON, Calif., May 29, 2024
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a
leader in single cell and spatial biology, announced today the
launch of its Xenium Prime 5K
Pan-Tissue and Pathways panel. The new assay features an enhanced
chemistry to increase plex by an order of magnitude while
delivering excellent per-gene sensitivity, improved specificity and
spatial fidelity, integrated multimodal cell segmentation, and
industry-leading speed and throughput.
"Seeing the Xenium Prime 5K data
reminded me of the excitement I experienced when I saw single cell
RNA-seq data for the first time," said Dr. Kevin Wei, M.D., Ph.D., Assistant Professor of
Medicine at Harvard Medical School.
"Now, we can identify relevant molecular pathways in human diseases
and explore new biological hypotheses, all from one glass
slide."
The high-plex Xenium Prime 5K
assay enables a new level of exploration for pathways, biomarkers,
ligand-receptor pairings and cell-cell interactions. Key features
include:
- Highest plex Xenium panel for comprehensive profiling of
cell types and states and cell signaling pathways across multiple
tissue and disease types.
- Excellent data quality to unlock mechanisms of disease,
therapeutics and cell behavior. The Xenium Prime 5K assay is optimized for performance and paired
with 10x Genomics' advanced multimodal cell segmentation, enabling
high sensitivity, specificity and spatial fidelity.
- Rapid turnaround time with easy, tissue-agnostic
workflows. 10x Genomics' industry-leading throughput enables
researchers to analyze up to 472 mm² of tissue in six days or
less.
- Easily customizable with up to 100 additional genes to
capture customers' specific research needs.
- Rigorously designed and developed using single cell
RNA-seq data from dozens of different organs and tissues, gene
expression profiles from hundreds of cell types and a screen of
more than 750,000 peer-reviewed publications to pinpoint highly
cited biomarkers.
"We successfully launched Xenium with a broad menu of
curated and highly customizable gene panels so customers could
target specific biology important for their research," said
Michael Schnall-Levin, Founding Scientist and Chief Technology
Officer at 10x Genomics. "With the launch of our 5K gene panel, researchers can now also use
Xenium for spatial exploration, enabling more biology and more
breakthroughs. This assay is yet another example of how we put our
innovation engine to work for our customers and build best-in-class
products that deliver best-in-class results."
The Xenium Prime 5K assay,
optimized for human and mouse species, is now available for
preorder and is expected to ship next month.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, capabilities, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-5-000-plex-gene-panel-for-xenium-302158495.html
SOURCE 10x Genomics, Inc